14 07, 2022

Regular use of ivermectin as prophylaxis for COVID-19 led up to 92% reduction in COVID-19 mortality rate in a dose-response manner: results of a prospective observational study of a strictly controlled population of 88,012 subjects among 223,128 participants

July 14, 2022|International, Ivermectin, Research|

Abstract

Background: We have previously demonstrated that ivermectin used as prophylaxis for COVID-19, irrespective of the regularity or the level of monitoring, in a strictly controlled city-wide program in Southern Brazil (Itajaí, SC, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates.

In […]

12 07, 2022

Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity

July 12, 2022|International, Ivermectin, Research, Treatment|

Ivermectin is an anti-parasitic agent that has gained attention as a potential COVID-19 therapeutic. It is a compound of the type Avermectin, which is a fermented by-product of Streptomyces avermitilis. Bifidobacterium is a member of the same phylum as Streptomyces spp., suggesting it may have a symbiotic relation with Streptomyces.

17 05, 2022

The New England Journal of Medicine published the fraudulent TOGETHER trial, designed and conducted to launch anti-ivermectin headlines across every major media outlet across the world.

May 17, 2022|Corruption, Inquiry, International, Ivermectin, Research|

Pierre Kory, MD, MPAMay 16

In part I of my post on the TOGETHER trial of ivermectin, I presented the context of this trial within Big Pharma’s decades-long Disinformation campaign against “science inconvenient to their interests.” I argued that no science has […]

16 02, 2022

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

February 16, 2022|Ivermectin, Research|

Abstract

Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients.